NCT04172779 2025-11-20
ECHO-B
University of Texas Southwestern Medical Center
Phase 2 Not yet recruiting
Clinical Trials
13 trialsNCT00977470 2025-10-15
Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT00885066 2025-09-30
Gemcitabine, Capecitabine, and Erlotinib in Treating Patients With Advanced Pancreatic Cancer
Centre Antoine Lacassagne
Phase 1 Completed
NCT00954226 2025-09-05
Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT04341181 2025-07-25
ProTarget
Rigshospitalet, Denmark
Phase 2 Recruiting
NCT06997068 2025-07-14
Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Oral Cavity Cancer in a Rural Midwest United States Population
Mayo Clinic
Phase 2 Recruiting
NCT00076310 2025-06-26
OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT00405405 2025-05-06
Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer
Thomas Jefferson University
Phase 1 Completed
NCT00954525 2025-05-02
Intravenous Vitamin C in Combination With Standard Chemotherapy for Pancreatic Cancer
Thomas Jefferson University
Phase 1 Completed
NCT00640978 2025-05-01
Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00942734 2025-05-01
Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00983307 2025-04-30
A Study of Erlotinib Plus Radiotherapy (RT) for Patients With Advanced or Inoperable Non-Small-Cell Lung Cancer
Thomas Jefferson University
Phase 2 Completed
NCT06483555 2025-04-16
PANGEA
UNC Lineberger Comprehensive Cancer Center
Phase 1/2 Recruiting